Skip to main content
SpringerLink
Log in

Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on neuropeptide metabolism in the rat brain

  • Original Article
  • Published:
Naunyn-Schmiedeberg's Archives of Pharmacology Aims and scope Submit manuscript

Abstract

The effect of a novel prolyl endopeptidase (PEP) inhibitor, (S)-2-[[(S)-2-(hydroxyacetyl)-l-pyrrolidinyl] carbonyl]-N-(phenylmethyl)-l-pyrrolidinecarboxamide (JTP-4819), on neuropeptide metabolism was investigated in the rat brain.

JTP-4819 exhibited a strong in vitro inhibitory effect on cortical and hippocampal PEP activity, with the IC50 values being approximately 0.58 ± 0.02 and 0.61 ± 0.06 nM, respectively. JTP-4819 also inhibited the in vitro degradation of substance P (SP), arginine-vasopressin (AVP), and thyrotropin-releasing hormone (TRH) by rat brain supernatants, with the IC50 values being respectively 3.4, 2.1, and 1.4 nM in the cerebral cortex and 3.3, 2.8, and 1.9 nM in the hippocampus. Oral administration of JTP-4819 at doses of 1 and 3 mg/kg increased SP-like immunoreactivity (LI) and AVP-LI in the cerebral cortex. JTP-4819 also increased hippocampal SP-LI and AVP-LI at doses of 1 and 3 mg/kg, as well as hippocampal TRH-LI at a dose of 3 mg/kg.

These findings suggest that JTP-4819 inhibited the degradation of SP, AVP, and TRH in the rat brain secondary to the inhibition of PEP, and thus increased cortical and hippocampal SP-LI and AVP-LI as well as hippocampal TRH-LI.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Aoyagi T, Wada T, Nagai M, Kojima F, Harada S, Takeuchi T, Takahashi H, Hirokawa K, Tumita T (1990) Deficiency of kallikrein-like enzyme activities in cerebral tissue of patients with Alzheimer's disease. Experientia 46:94–97

    Google Scholar 

  • Araujo DM, Lapchak PA, Robitaille Y, Gautheir S, Quirion R (1988) Differential alteration of various cholinergic markers in cortical and subcortical regions of human brain in Alzheimer's disease. J Neurochem 50:1914–1923

    Google Scholar 

  • Bartus RT, Dean III RL, Beer B, Lippa AS (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science 217:408–417

    Google Scholar 

  • Beal MF, Mazurek MIT (1987) Substance P-like immunoreactivity is reduced in Alzheimer's disease cerebral cortex. Neurology 37:1205–1209

    Google Scholar 

  • Biggins JA, Perry EK, Mcdermott JR, Smith AI, Perry RH, Edwardson JA (1983) Post mortem levels of thyrotropin-releasing hormone and neurotensin in the amygdala in Alzheimer's disease, schizophrenia and depression. J Neurol Sci 58:117–122

    Google Scholar 

  • Coyle JT, Donald LP, Delong MR (1983) Alzheimer's disease; A disorder of cortical cholinergic innervation. Science 219:1184–1190

    Google Scholar 

  • Crystal HA, Davies P (1982) Cortical Substance P-like immunoreactivity in cases of Alzheimer's disease and senile dementia of the Alzheimer type. J Neurochem 38:1781–1784

    Google Scholar 

  • Dalmaz C, Netto CA, Volkmer N, Dias RD, Izquierdo I (1986) Distribution of proline endopeptidase activity in sub-synaptosomal fractions of rat hypothalamus. Brazilian J Med Biol Res 19:685–690

    Google Scholar 

  • De Wied D (1984) The importance of vasopressin in memory. Trends Neurosci 7:62–64

    Google Scholar 

  • De Wied D, Gaffori O, Ree JM, Jong W (1984) Central target for the behavioral effects of vasopressin neuropeptides. Nature 308:276–280

    Google Scholar 

  • Dresdner K, Barker LA, Orlowski M, Wilk S (1982) Subcellular distribution of prolyl endopeptidase and cation-sensitive neutral endopeptidase in rabbit brain. J. Neurochem 38:1151–1154

    Google Scholar 

  • Faden AI, Salzman S (1992) Pharmacological strategics in CNS trauma. Trends Pharmacol Sci 13:29–35

    Google Scholar 

  • Ferrier IN, Cross AJ, Johnson JA, Roberts GW, Crow TJ, Corsellis JAN, Lee YC, O'shaughnessy D, Adrian TE, Mcgregor GP, Baracese-Hamilton AJ, Bloom SR (1983) Neuropeptides in Alzheimer type dementia. J Neurol Sci 62:159–170

    Google Scholar 

  • Fujiyoshi K, Suga H, Okamoto K, Nakamura S, Kameyama M (1987) Reduction of arginine-vasopressin in the cerebral cortex in Alzheimer type senile dementia. J Neurol Neurosurg Psychiatry 50:929–932

    Google Scholar 

  • Griffiths EC (1987) Clinical applications of thyrotropin-releasing hormone. Clin Sci 73:449–457

    Google Scholar 

  • Griffiths EC, Baris C, Visser TJ, Klootwijk W (1985) Thyrotropin-releasing hormone inactivation by human postmortem brain. Regul Pept 10:145–155

    Google Scholar 

  • Hasenöhrl RU, Huston JP, Schuumman T (1990) Neuropeptide substance P improves water maze performance in aged rats. Psychopharmacology 101:23–26

    Google Scholar 

  • Husain MM, Nemeroff CB (1990) Neuropeptides and Alzheimer's disease. J Am Geriatr Soc 38:918–925

    Google Scholar 

  • Huston JP, Hasenohrl RU, Gerhardt P, Schwarting RKW (1993) Sequence-specific effects of neurokinin substance P on memory, reinforcement and brain dopamine activity. Psychopharmacology 112:147–162

    Google Scholar 

  • Ishiura S, Tsukahara T, Tabira T, Shimizu T, Arahata K, Sugita H (1990) Identification of a putative amyloid A4-generating enzyme as a prolyl endopeptidase. FEBS Lett 260:131–134

    Google Scholar 

  • Kalwant S, Porter AG (1991) Purification and characterization of human brain prolyl endopeptidase. Biochem J 276:237–244

    Google Scholar 

  • Kato T, Inomata Y, Takeda K (1993) Determination of the axonally transported substance P-like imunoreactivity in rat sciatic nerves with a newly developed EIA method. Neurochem Res 18:818

    Google Scholar 

  • Knisatschek H, Bauer K (1986) Specific inhibition of post proline cleaving enzyme by benzyloxycarbonyl-Gly-Pro-Diazomethyl ketone. Biochem Biophys Res Commun 134:888–894

    Google Scholar 

  • Koida M, Walter R (1976) Post-proline cleaving enzyme. J Biol Chem 251:7593–7599

    Google Scholar 

  • Kowall NW, Beal MF, Busciglio J, Duffy LK, Yankner BA (1991) An in vivo model for the neurogenerative effects of β-amyloid and protection by Substance P. Proc Natl Acad Sci USA 88:7247–7251

    Google Scholar 

  • Lippa AS, Pelham RW, Beer B, Critchett DJ, Dean RL, Bartus RT (1980) Brain cholinergic dysfunction and memory in aged rats. Neurobiol Aging 1:13–19

    Google Scholar 

  • Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193:265–275

    Google Scholar 

  • Mazurek MF, Beal MF, Martin JB (1985) Vasopressin in postmortem Alzheimer brain. Ann Neurol 18:143

    Google Scholar 

  • Mazurek MF, Beal MF, Bird ED, Martin JB (1986) Vasopressin in Alzheimer's disease: A study of postmortem brain concentrations. Ann Neurol 20:665–670

    Google Scholar 

  • O'leary RM, O'connor B (1995) Identification and localisation of a synaptosomal membrane prolyl endopeptidase from bovine brain. Eur J Biochem 227:277–283

    Google Scholar 

  • Oram J, Edwardson J, Millard P (1981) Investigation of cerebrospinal fluid neuropeptides in idiopathic senile dementia. Gelontology 27:216–223

    Google Scholar 

  • Perry EK (1986) The cholinergic hypothesis. Ten years on. Br Med Bull 42:63–69

    Google Scholar 

  • Rossor MN, Emson PC, Dawbarn D, Mountjoy CQ, Roth M (1986) Neuropeptides and dementia. Progr Brain Res 66: 143–159

    Google Scholar 

  • Sarter M (1991) Taking stock of cognition enhancers. Trends Pharmacol Sci 12:456–461

    Google Scholar 

  • Schlesinger K, Lipsitz DU, Peck PL, Pelleymounter MA, Stewart JM, Chase TN (1983) Substance P enhancement of passive and active avoidance conditioning in mice. Pharmacol Biochem Behav 19:655–661

    Google Scholar 

  • Selkoe DJ (1989) Aging, amyloid, and Alzheimer's disease. N Engl J Med 320:1484–1487

    Google Scholar 

  • Selkoe DJ (1990) Deciphering Alzheimer's disease: the amyloid precursor protein yields new clues. Science 248:1058–1060

    Google Scholar 

  • Suzuki H, Yoshioka M, Yanagisawa M, Urayama O, Kurihara T, Hosoki R, Saito K, Otsuka M (1994) Involvement of enzymatic degradation in the inactivation of tachykinin neurotransmitters in neonatal rat spinal cord. Br J Pharmacol 113:310–316

    Google Scholar 

  • Taira K, Kaneto H (1987) Experimental models for studying the avoidance response in mice and the anti-amnesic effect of prolylendopeptidase inhibitors. Folia Pharmacol Jpn (in Japanese) 89:243–252

    Google Scholar 

  • Taylor WL, Dixon JE (1980) Catabolism of neuropeptides by a brain proline endopeptidase. Biochem Biophys Res Commun 94:9–15

    Google Scholar 

  • Toide K, Shinoda M, Uemura A (1994) Effect of JTP-4819, a novel prolyl endopeptidase (PEP) inhibitor, on passive avoidance response and Morris water maze task. Jpn J Psychopharmacol 14:454 [Suppl]

    Google Scholar 

  • Toide K, Iwamoto Y, Fujiwara T, Abe H (1995a) JTP-4819: A novel prolyl endopeptidase inhibitor with potential as a congnitive enhancer. J Pharmacol Exp Ther 274:1370–1378

    Google Scholar 

  • Toide K, Okamiya K, Iwamoto Y, Kato T (1995b) Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on PEP activity and substance P- and arginine-vasopressin-like immunoreactivity in the brains of aged rats. J Neurochem 65:234–240

    Google Scholar 

  • Walter R, Shlank H, Glass JD, Schwartz IL, Kerenyi TD (1971) Leucylglycinamide released from oxytocin by human enzyme. Science 173:827–829

    Google Scholar 

  • Walter R, Simmons WH, Yoshimoto T (1980) Proline specific endo-and exopeptidases. Mol Cell Biochem 30:111–127

    Google Scholar 

  • Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delong MR (1982) Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain. Science (Wash. DC) 215: 1237–1239

    Google Scholar 

  • Wilk S (1983) Mini review prolyl endopeptidase. Life Sci 33:2149–2157

    Google Scholar 

  • Yankner BA, Duffy LK, Kirschner DA (1990) Neurotropic and neurotoxic effects of amyloid β-protein: reversal by tachykinin neuropeptides. Science 250:279–282

    Google Scholar 

  • Yoshimoto T (1991) Proline specific peptidases and their specific inhibitors. Yakugaku Zasshi (in Japanese) 111:345–358

    Google Scholar 

  • Yoshimoto T, Ogita K, Walter R, Koida M, Tsuru O (1979) Synthesis of a new fluorogenic substrate and distribution of the endopeptidase in rat tissues and body fluids of man. Biochim Biophys Acta 569:184–192

    Google Scholar 

  • Yoshimoto T, Nishimura T, Kita T, Tsuru D (1983) Post-proline cleaving enzyme (Prolyl endopeptidase) from bovine brain. J. Biochem 94:1179–1190

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1, Murasaki-cho, Takatsuki, 569, Osaka, Japan

    K. Toide, T. Fujiwara, Y. Iwamoto, M. Shinoda & K. Okamiya

  2. Laboratory of Molecular Recognition, Yokohama City University, Yokohama, 236, Kanagawa, Japan

    T. Kato

Authors
  1. K. Toide
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Fujiwara
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y. Iwamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Shinoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K. Okamiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T. Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Toide, K., Fujiwara, T., Iwamoto, Y. et al. Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on neuropeptide metabolism in the rat brain. Naunyn-Schmiedeberg's Arch Pharmacol 353, 355–362 (1996). https://doi.org/10.1007/BF00168640

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00168640

Keywords

Search

Navigation